Active Ingredient History
Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase - the key enzyme mediating HCV RNA replication. Sofosbuvir is a prodrug and after ingestion it is rapidly converted to GS-331007, the predominant circulating drug that accounts for greater than 90% of the systemically active drug. The compound GS-331007 is efficiently taken up by hepatocytes, whereby cellular kinases convert GS-331007 to its pharmacologically active uridine analog 5’-triphosphate form (GS-461203). This triphosphate compound mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in chain termination. The active form GS-461203 targets the NS5B catalytic site and acts as a non-obligate chain terminator. The active compound (GS-461203) does not inhibit host DNA polymerases, RNA polymerases, or mitochondrial RNA polymerase. Sofosbuvir (alone or in in combination with other medications) is used to treat Hepatitis C. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
beta-Thalassemia (Phase 4)
Bone Diseases, Metabolic (Phase 4)
Buprenorphine (Phase 4)
Carcinoma, Hepatocellular (Phase 4)
Cardiovascular Diseases (Phase 4)
Coinfection (Phase 4)
COVID-19 (Phase 4)
Cryoglobulinemia (Phase 2/Phase 3)
Diabetes Mellitus (Phase 4)
Drug Misuse (Phase 4)
Drug Users (Phase 4)
Fibrosis (Phase 4)
Gaucher Disease (Phase 4)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 4)
Heart Transplantation (Phase 2)
Hematologic Neoplasms (Phase 1/Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 4)
Hepacivirus (Phase 3)
Hepatitis (Phase 1)
Hepatitis B (Phase 2/Phase 3)
Hepatitis B, Chronic (Phase 4)
Hepatitis C ()
Hepatitis, Chronic (Phase 2)
Hepatitis E (Phase 2)
HIV (Phase 4)
HIV Infections (Phase 4)
Hypertension, Portal (Phase 2)
Infertility, Male (Phase 2/Phase 3)
Insulin Resistance (Phase 4)
Kidney (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 2/Phase 3)
Liver (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Diseases (Phase 4)
Liver Transplantation (Phase 4)
Lung Diseases (Phase 1/Phase 2)
Lung Diseases, Interstitial (Phase 4)
Lung Transplantation (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Metabolic Syndrome (Phase 2/Phase 3)
Methadone (Phase 4)
Neoplasms (Phase 4)
Opioid-Related Disorders (Phase 4)
Organ Transplantation (Phase 4)
Pharmacology (Phase 4)
Pregnancy (Phase 1)
Pregnancy Complications (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Renal Insufficiency (Phase 4)
Respiratory Insufficiency (Phase 4)
Severe Acute Respiratory Syndrome (Phase 2)
Substance Abuse, Intravenous (Phase 3)
Thalassemia (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue